Merck plans mega takeover from Verona Pharma: billion-dollar deal ahead!
Merck plans mega takeover from Verona Pharma: billion-dollar deal ahead!
Verona, Vereinigtes Königreich - Merck & Co. strives for a billion-dollar takeover of the British biotech company Verona Pharma. According to reports from Exxpress.at Planning the negotiations that are located in an advanced stage may already be known this week. The intended purchase price amounts to $ 107 per American Depository Share (ADS), which corresponds to a surcharge of 23 percent on the last noted course. Overall, Verona Pharma's assessment would be around $ 10 billion.
Die Übernahme erfolgt besonders vor dem backdrop des Patentablaufs von Mercks umsatzstärkstem Medikament, Keytruda. This drug generated almost $ 30 billion in sales in 2024 and will be patent-free 2028. Merck has prompted the pressure to diversify income sources in order to avoid taking over future sales by generic competition. Analysts predict that Mercks pipeline could be significantly expanded by the inhaled medication ohtuvayre, which is approved for the treatment of chronic obstructive lung diseases (COPD).
strategic focus on biotech takeovers
Verona Pharma has made a name for itself with Ohtuvayre, which was already approved and generated over 96% of sales in the first quarter of 2025. A total of about $ 76 million of the proceeds came from this therapy, which hits around 16 million Americans, as
A look into the future of the pharmaceutical industry
like warkely.de determine the market strategies from original manufacturers significantly influence the market strategies. After a patent has expired, generics can come onto the market that press prices and attack the market shares of the original manufacturers. This dynamic requires innovative solutions from companies to claim their position what makes Verona Pharma a critical step for Merck.
Through new strategies, such as "patent clustering" and reformulating existing medication, companies try to extend patent protection and secure their market shares. At a time when the industry is traditionally characterized by quick decisions and innovations, Merck's potential deal with Verona Pharma could set the course for future growth. The increasing digitization and the focus on personalized medicine could also influence the market adjustments after the end of patents.
| Details | |
|---|---|
| Ort | Verona, Vereinigtes Königreich |
| Quellen | |
Kommentare (0)